Michael J. Ciesielski, PhD

Dr. Ciesielski is a co-inventor of the survivin vaccine technology on which MimiVax was founded. He joined the Academic Faculty of Roswell Park Comprehensive Cancer Center in 2004 after obtaining his PhD in Immunology from the State University of New York at Buffalo. Prior to this, he earned a BS in Biology/Biotechnology from Niagara University and a Master’s degree from the State University of New York at Buffalo, after which he established the Neuro-Oncology laboratory at Roswell Park together with Dr. Fenstermaker.

He is an Assistant Professor of Neurosurgery and Oncology at Roswell Park and a member of the Graduate Faculty of the University at Buffalo Jacobs School of Medicine and Biomedical Sciences. He has co-authored more than 50 journal articles and numerous abstracts, and is an active member of the Society for Neuro-Oncology (SNO), American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO) and the Biotechnology Innovation Organization (BIO).

Dr. Ciesielski was honored with a Research Scholar Award from the American Cancer Society and the Glioblastoma Award from the National Brain Tumor Foundation, and was named a Top C-Level Executive by Buffalo ‘612. He holds 22 global patents, 21 of which are for survivin-based technology.